Status: Recruiting
Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination
* Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination * Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination
Participants needed: 230
Trial details
Phase: Phase 2Age: 4-6Biological sex: AllType: InterventionalSponsor: Green Cross CorporationUpdated: Jan 24, 2024Locations: 1
Eligibility criteria
Healthy children between 4 and 6 years of age as of the date of written consent [+3]
Subjects with a history of exposure to varicella through contact with a varicell... [+17]